Fucoidan can function as an adjuvant in vivo to enhance dendritic cell maturation and function and promote antigen-specific T cell immune responses

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Jin, Jun O ^a   Zhang, Wei ^a   Du, Jiang Yuan ^a   Wong, Ka Wing ^a   Oda, Tatsuya ^b   Yu, Qing ^c  

^a FUDAN UNIVERSITY   (China)

^b NAGASAKI UNIVERSITY   (Japan)

^c FORSYTH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; FUCOIDIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; EPITOPE; IMMUNOLOGICAL ADJUVANT; POLYSACCHARIDE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL PROTECTION; CELL SPECIFICITY; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ACTIVITY; HUMAN; HUMAN CELL; IMMUNITY; IMMUNIZATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MOUSE; NONHUMAN; SPLEEN; T LYMPHOCYTE; TC1 CELL; TH1 CELL; TUMOR CELL; UPREGULATION; ANIMAL; ANTIBODY PRODUCTION; CELL DIFFERENTIATION; CYTOLOGY; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; INFLAMMATION MEDIATORS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; OVALBUMIN; POLYSACCHARIDES; SPLEEN; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84902670001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099396     Document Type: Article

References (34)

1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245-252. (Pubitemid 28155090)
2. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nature reviews Immunology 5: 296-306. (Pubitemid 40516155)
3. Pooley JL, Heath WR, Shortman K (2001) Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. Journal of immunology 166: 5327-5330. (Pubitemid 32374150)
4. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, et al. (2006) The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proceedings of the National Academy of Sciences of the United States of America 103: 10729-10734. (Pubitemid 44078044)
5. Shortman K, Heath WR (2010) The CD8 + dendritic cell subset. Immunological reviews 234: 18-31.
6. Watts C (2004) The exogenous pathway for antigen presentation on major histocompatibility complex class II, CD1 molecules. Nature immunology 5: 685-692.
7. Gordon S (2002) Pattern recognition receptors: doubling up for the innate immune response. Cell 111: 927-930.
8. Barr TA, Brown S, Ryan G, Zhao J, Gray D (2007) TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. European journal of immunology 37: 3040-3053. (Pubitemid 350131284)
9. Kawai T, Akira S (2008) Toll-like receptor and RIG-I-like receptor signaling. Annals of the New York Academy of Sciences 1143: 1-20.
10. Dubensky TW, Jr., Reed SG (2010) Adjuvants for cancer vaccines. Seminars in immunology 22: 155-161.
11. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nature reviews Cancer 12: 265-277.
12. Palucka K, Ueno H, Banchereau J (2011) Recent developments in cancer vaccines. Journal of immunology 186: 1325-1331.
13. Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nature immunology 5: 7-10. (Pubitemid 38081459)
14. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
15. Fitton JH (2011) Therapies from fucoidan; multifunctional marine polymers. Marine drugs 9: 1731-1760.
16. Kwak JY (2014) Fucoidan as a marine anticancer agent in preclinical development. Marine drugs 12: 851-870.
17. Thelen T, Hao Y, Medeiros AI, Curtis JL, Serezani CH, et al. (2010) The class A scavenger receptor, macrophage receptor with collagenous structure, is the major phagocytic receptor for Clostridium sordellii expressed by human decidual macrophages. Journal of immunology 185: 4328-4335.
18. Hayashi K, Nakano T, Hashimoto M, Kanekiyo K, Hayashi T (2008) Defensive effects of a fucoidan from brown alga Undaria pinnatifida against herpes simplex virus infection. International immunopharmacology 8: 109-116. (Pubitemid 350199103)
19. Hu Y, Cheng SC, Chan KT, Ke Y, Xue B, et al. (2010) Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells. Biochemical and biophysical research communications 392: 329-334.
20. Kawashima T, Murakami K, Nishimura I, Nakano T, Obata A (2012) A sulfated polysaccharide, fucoidan, enhances the immunomodulatory effects of lactic acid bacteria. International journal of molecular medicine 29: 447-453.
21. Kim MH, Joo HG (2008) Immunostimulatory effects of fucoidan on bone marrow-derived dendritic cells. Immunology letters 115: 138-143.
22. Yang M, Ma C, Sun J, Shao Q, Gao W, et al. (2008) Fucoidan stimulation induces a functional maturation of human monocyte-derived dendritic cells. International immunopharmacology 8: 1754-1760.
23. Jin JO, Park HY, Xu Q, Park JI, Zvyagintseva T, et al. (2009) Ligand of scavenger receptor class A indirectly induces maturation of human blood dendritic cells via production of tumor necrosis factor-alpha. Blood 113: 5839-5847.
24. Hermans IF, Silk JD, Yang J, Palmowski MJ, Gileadi U, et al. (2004) The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. Journal of immunological methods 285: 25-40. (Pubitemid 38186583)
25. Mori N, Nakasone K, Tomimori K, Ishikawa C (2012) Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. World journal of gastroenterology: WJG 18: 2225-2230.
26. Azuma K, Ishihara T, Nakamoto H, Amaha T, Osaki T, et al. (2012) Effects of oral administration of fucoidan extracted from Cladosiphon okamuranus on tumor growth and survival time in a tumor-bearing mouse model. Marine drugs 10: 2337-2348.
27. Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H (2003) Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochemical pharmacology 65: 173-179. (Pubitemid 36015820)
28. Takeda K, Tomimori K, Kimura R, Ishikawa C, Nowling TK, et al. (2012) Anti-tumor activity of fucoidan is mediated by nitric oxide released from macrophages. International journal of oncology 40: 251-260.
29. Cao T, Ueno H, Glaser C, Fay JW, Palucka AK, et al. (2007) Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL. European journal of immunology 37: 2657-2667. (Pubitemid 47423633)
30. Banchereau J, Thompson-Snipes L, Zurawski S, Blanck JP, Cao Y, et al. (2012) The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. Blood 119: 5742-5749.
31. Miconnet I, Coste I, Beermann F, Haeuw JF, Cerottini JC, et al. (2001) Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. Journal of immunology 166: 4612-4619. (Pubitemid 32233747)
32. Santiago-Garcia J, Kodama T, Pitas RE (2003) The class A scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix. The Journal of biological chemistry 278: 6942-6946. (Pubitemid 36800687)
33. Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, et al. (2007) The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. Journal of immunology 178: 748-756. (Pubitemid 46098855)
34. Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, et al. (2013) Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer research 73: 6597-6608.